Biotech Stocks Perk Up on Shire/ViroPharma Merger
Sweet Spot of The Market- Mid-Caps With Sales Growth
One of the core Rayno Biopharmaceutical stock picks is up 25% to $49.37 in a $4.2B deal. ViroPharma, Inc. is a rare disease drug Company whose commercial product CIN-RYZE is a leading brand for the prophylactic treatment of Hereditary Angioedema (HAE).Revenues for ViroPharma in Q3 were $133M with a Net Income of $4.186M. Forecasted revenues for 2014 are $566M valuing the acquisition at 7.4X.
ViroPharma (VPHM) was added to the Rayno Life Science Portfolio on 2/2/09 at $12 for a 4X return.